Anzeige
Mehr »
Samstag, 25.07.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MU8Y | ISIN: ES0157097017 | Ticker-Symbol: E2Z
Tradegate
24.07.26 | 11:07
11,460 Euro
+3,43 % +0,380
Branche
Pharma
Aktienmarkt
IBEX MEDIUM CAP
1-Jahres-Chart
ALMIRALL SA Chart 1 Jahr
5-Tage-Chart
ALMIRALL SA 5-Tage-Chart
RealtimeGeldBriefZeit
11,12011,24024.07.
11,14011,20024.07.

Aktuelle News zur ALMIRALL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAlmirall SA H1 Profit Rises2
FrAlmirall H1 2026 slides: margin target hit early, biologics drive growth3
FrAlmirall verfehlt Gewinnprognose - schwächeres Ebglyss-Wachstum belastet Ausblick39
FrALMIRALL, S.A.: Almirall announces that it will webcast a conference to introduce and explain the results for the first half of 20267
FrALMIRALL, S.A.: Almirall files First Half results presentation for 20262
FrAlmirall, S.A.: Almirall H1 2026 Results452Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business reiterating guidance aligned with long-term growth trajectory...
► Artikel lesen
DiAlmirall's paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance4
MoAlmirall, S.A.: Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older372The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study....
► Artikel lesen
ALMIRALL Aktie jetzt für 0€ handeln
30.06.ALMIRALL, S.A.: Almirall divests its Actithiol franchise20
03.06.ALMIRALL, S.A.: Information on dividends15
13.05.XFRA CAPITAL ADJUSTMENT INFORMATION - 13.05.2026454Das Instrument 7HW0 SE0027099078 WYLD NETWORKS AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.05.2026 The instrument 7HW0 SE0027099078 WYLD NETWORKS AB EQUITY is traded ex capital adjustment on...
► Artikel lesen
11.05.Almirall, S.A. reports Q1 results13
11.05.Contribution from Almirall's equity swap turned from positive in Q1 2025 to negative in Q1 2026, accounting for 29.2% fall in net profit to €15.3 million14
11.05.Almirall Q1 2026 slides: biologics surge offsets modest revenue miss1
11.05.Almirall SA mit gemischten Q1-Zahlen: Umsatz verfehlt Prognosen, Profitabilität überzeugt7
11.05.Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations - Led by 19.3% YoY Growth of Its European Dermatology Business698Almirall's European Dermatology business delivered solid growth of 19.3% YoY, reaching €166.3 MM in Q1 2026, driven by strong momentum across key growth drivers. This contributed to overall Net...
► Artikel lesen
11.05.ALMIRALL, S.A.: Information on Dividend calendar4
11.05.ALMIRALL, S.A.: Resolutions approved by the General Shareholders' Meeting 20263
11.05.ALMIRALL, S.A.: Almirall announces that it will webcast a conference to introduce and explain the first quarter 2026 results2
11.05.ALMIRALL, S.A.: Resolutions approved by the Board of Directors4
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1